Business

Hot Stocks: Brokerages view on HDFC Bank, Apollo Hospitals, M&M and Tata Steel

Brokerage houses such as CLSA downgraded Tata Steel to sell and M&M to outperform from a buy rating earlier. Morgan Stanley maintained an overweight rating on Apollo Hospitals and HSBC gave a buy tag to HDFC Bank.

We have collated a list of recommendations from top brokerage firms from ETNow and other sources:

CLSA on Steel stocks: Tata Steel, JSW Steel and JSPL

CLSA downgraded Tata Steel to sell from outperform and has also slashed the target price to Rs 135 from Rs 145. The global investment bank also downgraded JSW Steel to a sell from underperform and has also slashed the target price to Rs 730 from Rs 810.

CLSA maintained an underperform rating on JSPL but raised the target price to Rs 840 from Rs 820.

The profit pool in India should incrementally move towards miners from converters as steel capacity addition picks up pace. The valuations for steel stocks have risen, while spreads are at a trough. Consensus estimates are not factoring in spread compression.

The brokerage believes that JSPL is relatively better off, as weaker industry spreads will be more than offset by the margin expansion projects. A broad-based demand-driven stimulus in China is a key risk to our thesis, said the note.

CLSA on M&M: Outperform | Target: Rs 2,115

CLSA downgraded M&M to outperform from a buy earlier but raised the target price to Rs 2,115 from Rs 2,074 earlier. The downgrade is followed by a recent rally seen in the stock price. Over the longer term, it should flourish owing to greater exposure to premium products.

Morgan Stanley on Apollo Hospitals: Overweight | Target: Rs 7,181

Morgan Stanley maintained an overweight rating on Apollo Hospitals with a target price of Rs 7,181. A pan-India price cap on surgical procedures is unlikely because of the complexity and challenges involved in implementing such a cap. The global investment bank remains positive on Apollo Hospital’s long-term growth story.

For most private players, cash and insurance account for -70% of the payor profile. High-end tertiary care contributes to more than half of total revenues. Apollo derives 60% of its revenues from high-end tertiary care and 80% are cash and insurance patients, the brokerage note said.

HSBC on HDFC Bank: Buy | Target: Rs 1,750

HSBC maintained a buy rating on HDFC Bank with a target of Rs 1,750. Lower loan growth might be a catalyst. Expectations of high loan growth, not deposits, are at the core of recent disappointments. Therefore, lowering loan growth may be beneficial for the stock.

It would be positive for the NIM/RoA outlook. HDFC Bank’s stock offers possible returns of a 15-29% CAGR over FY24-27e from current levels.

(Disclaimer: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)

Related Articles

Back to top button